Chuangyebang was informed that Beijing Jingda Biotechnology Co., Ltd. (hereinafter referred to as “Jingda Bio”) recently announced the completion of tens of millions of yuan in Pre-A round of financing. This round of financing was led by Jinke Junchuang, with participation from Deyuan Pharmaceutical, Zhiheng Ventures and other institutions.
The financing funds will be mainly used to promote the company’s first CAR-NK cell drug JDC06 injection into clinical research and enrich the preclinical research of the solid tumor product pipeline.
Jingda Bio is a global innovative drug research and development enterprise focusing on the development of allogeneic off-the-shelf NK/CAR-NK cell drugs. It was co-founded by biopharmaceutical industry executives, new drug review experts, senior researchers and clinicians. , APE-CAR-NK gene modification, new viral vectors, etc. have rich industrial experience, and have won many honorary qualifications such as national high-tech enterprises and Zhongguancun high-tech enterprises. Its first allogeneic cell drug JDC06 injection for hematological tumors is about to enter the clinical research stage, and its product pipeline covers many unmet clinical needs of hematological tumors and solid tumors.
Dr. Leiming Guo, General Manager of Jingda Bio, said: “We are very honored to be recognized and supported by well-known investment institutions in the field of biomedicine at home and abroad. Jingda Bio has a leading “allogeneic-spot” immune cell development platform, and has independently developed “APE-NK” cell gene modification technology, this therapy is expected to break through the bottleneck of the current clinical treatment of solid tumors, and the future growth is very worth looking forward to. The successful completion of this financing is a new milestone in the company’s development history, and will accelerate the innovative research and development of key pipelines and clinical research, while attracting and cultivating outstanding talents, and developing the company into a strong innovation-driven new drug research and development enterprise.”
media coverage
A new start-up state in the investment world
This article is reprinted from: https://readhub.cn/topic/8h4JNUN3jPr
This site is for inclusion only, and the copyright belongs to the original author.